6-Fluoro-DET


6-Fluoro-DET, or 6-F-DET, also known as 6-fluoro-N,''N''-diethyltryptamine, is a substituted tryptamine derivative related to psychedelic drugs such as diethyltryptamine.

Use and effects

6-Fluoro-DET produces physiological effects but does not produce hallucinogenic effects in humans.

Pharmacology

Pharmacodynamics

6-Fluoro-DET acts as a partial agonist at the serotonin 5-HT2A receptor, but while it produces similar physiological effects to psychedelics, it does not appear to produce psychedelic effects itself even at high doses. Relatedly, 6-F-DET does not substitute for LSD in drug discrimination tests and does not produce the head-twitch response in rodents. For the preceding reasons, it saw some use as an active placebo in early clinical trials of psychedelic drugs, but was regarded as having little use otherwise, though more recent research into compounds such as AL-34662, tabernanthalog, and zalsupindole has shown that these kind of non-psychedelic serotonin 5-HT2A agonists can have various useful applications.
A hypothesis for the lack of head-twitch response in mice and hallucinogenic effects in humans is that 6-F-DET acts as a 5-HT2A receptor partial agonist of the Gq signaling pathway. This hypothesis explains the lack of hallucinogenic effects of other 5-HT2A receptor ligands, which are also weak Gq agonists and below the efficacy threshold found to induce psychedelic effects, like 25N-N1-Nap, 2-Br-LSD, lisuride, tabernanthalog, and 6-MeO-DMT.

Chemistry

Analogues

Analogues of 6-fluoro-DET include 6-fluoro-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 5-fluoro-AMT, 6-fluoro-AMT, 6-methyl-DMT, 6-MeO-DMT, 6-hydroxy-DMT, and bretisilocin, among others.

History

6-Fluoro-DET was first described in the scientific literature by Stephen Szara and colleagues by 1963.